New asthma inhaler tested in teens: early safety check
NCT ID NCT07065331
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single inhaled dose of a new drug called AZD8630 in 10 teenagers with asthma. The main goal was to see how the drug moves through the body and to check for any safety issues. Participants used a dry powder inhaler and were monitored for side effects and immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
10 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Physician prescribed daily use of asthma medication. * Pre-bronchodilator Forced expiratory volume in one second (FEV1) ≥ 50% of the predicted normal value. * Asthma control questionnaire-5 (ACQ-5) \< 1.5 at Screening and Study Day 1. Key Exclusion Criteria: * History of any clinically important disease or disorder. * History of any chronic respiratory disorders (except asthma). * Acute exacerbation of asthma within 4 weeks of Screening. * Life -threatening asthma. * Completed treatment for respiratory infection with antibiotics within 4 weeks of Screening. * History of acquired or inherited immunodeficiency disorders. * Oral immunotherapy, including stable maintenance dose allergen-specific oral immunotherapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Bakersfield, California, 93301, United States
-
Research Site
Miami Lakes, Florida, 33014, United States
-
Research Site
Lafayette, Louisiana, 70508, United States
-
Research Site
Raleigh, North Carolina, 27607, United States
-
Research Site
Toledo, Ohio, 43617, United States
-
Research Site
Oklahoma City, Oklahoma, 73120, United States
-
Research Site
Spartanburg, South Carolina, 29303, United States
-
Research Site
Boerne, Texas, 78006, United States
-
Research Site
Salt Lake City, Utah, 84107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple breath test cut asthma Flare-Ups?
- Breathing tests face off: can extra lung measurements improve asthma diagnosis?
- The carbon label on your inhaler: can it sway a Doctor's choice?
- Six biologics put to the test in Real-World asthma and COPD care
- Can a digital program help teens with chronic illnesses move to adult care?
- Why do some kids catch every cold? a 1,200-Child study hunts for immune clues